NCT07227922PHASE1RecruitingAccepts Healthy Volunteers
Clofutriben Pharmacokinetics in Patients With Impaired Renal Function
Sparrow Pharmaceuticals
Start Date
11/30/2025
Completion Date
7/1/2026
Summary
This is a Phase 1, single-center, open-label, single-dose trial. Sixteen participants are planned: 8 participants with moderate renal impairment and 8 matched control participants with normal renal function.
Detailed Description
Following Screening, enrolled participants will be confined to a clinical research unit for 6 days. Each participant will receive a single oral dose of clofutriben. Clofutriben PK, safety, and tolerability will be assessed. The participants will be contacted by telephone 4 weeks after clofutriben administration for safety follow-up.
Eligibility Criteria
Age Range: 18 years to 83 years
Inclusion Criteria:
* Male and female participants with stable moderate renal impairment (estimated glomerular filtration rate \[eGFR\]: 30 to \<60 mL/min) and matched (by sex, age, and weight) control participants with normal renal function (eGFR: ≥90 mL/min) will be enrolled in this trial.
Exclusion Criteria:
* Participant whose current or recent medical conditions, medications, or procedures could increase participant's safety risk, or whom the Investigator considers not suitable for entry into the trial or the participant, or who has clinically significant abnormal 12-lead electrocardiogram (ECG)/ vital sign measurements/ laboratory test results at Screening and Check-in, will not be enrolled
Interventions
DRUG
12mg clofutriben
Conditions
Moderate Renal Impairment
Locations
Orlando Clinical Research Center
Orlando, Florida 32809
United States